Area of research
Molecular Biology · Nephrology
Research interest
Research interests include Amyloidosis: Diagnosis, Treatment, Outcomes, Parathyroid Disorders and Treatments, Alzheimer's disease research and treatments, and Protein Kinase Regulation and GTPase Signaling.
Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience
A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosis
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis
Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease
Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis
Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure
Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis
A new era of amyloidosis: the trends at a major US referral centre
Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)
Features of Atrial Fibrillation in Wild-Type Transthyretin Cardiac Amyloidosis: A Systematic Review and Clinical Experience
Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease
Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis
Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model
Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant
Oxidative post-translational modifications of an amyloidogenic immunoglobulin light chain protein
Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain‐mediated cardiotoxicity
Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt)
Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity
Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis
Homozygosity for the V122I Mutation in Transthyretin Is Associated with Earlier Onset of Cardiac Amyloidosis in the African American Population in the Seventh Decade of Life
Transthyretin Aggregate-Specific Antibodies Recognize Cryptic Epitopes on Patient-Derived Amyloid Fibrils